Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 15,050 KRW
Change Today +100.00 / 0.67%
Volume 424.6K
115450 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 2:28 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

g-treebnt co ltd (115450) Snapshot

Open
14,950
Previous Close
14,950
Day High
15,500
Day Low
14,300
52 Week High
06/17/15 - 16,700
52 Week Low
01/16/15 - 2,700
Market Cap
305.3B
Average Volume 10 Days
417.9K
EPS TTM
-76.18
Shares Outstanding
20.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for G-TREEBNT CO LTD (115450)

Related News

No related news articles were found.

g-treebnt co ltd (115450) Related Businessweek News

No Related Businessweek News Found

g-treebnt co ltd (115450) Details

G-treeBNT Co., Ltd. researches and develops multimedia software in South Korea and internationally. The company offers FXUI, a middleware for embedded 2D GUI, which supports diverse hardware and software environment; FXUI-3D, an embedded GUI middleware solution for emerging 3D graphics; and FXUI-S3D, a solution to support stereoscopic 3D (S3D) screen display, and framework for S3D contents production and display. It also provides FX-Studio, an integrated solution for use in content development with embedded devices. In addition, the company produces pumps, motors, and other components; and focuses on drama production. Further, it develops pharmaceutical products. The company was formerly known as Digital Aria, Co., Ltd. and changed its name to G-treeBNT Co., Ltd. in 2014. G-treeBNT Co., Ltd. was founded in 2000 and is based in Seongnam, South Korea.

Founded in 2000

g-treebnt co ltd (115450) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

g-treebnt co ltd (115450) Key Developments

G-treeBNT Co., Ltd., Annual General Meeting, Mar 31, 2015

G-treeBNT Co., Ltd., Annual General Meeting, Mar 31, 2015., at 09:00 Korea Standard Time.

Regenerx Biopharmaceuticals and G-treeBNT Co., Ltd. Partner to Develop RGN-259 in the US for Ophthalmic Indications

RegeneRx Biopharmaceuticals reported the launch of an agreement to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the US in partnership with G-treeBNT Co. This joint venture (JV) agreement allows G-treeBNT to conduct and fund all clinical trials and product development through approval of a new drug application (NDA). Under the license agreement, RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell it's RGN-259 in the US as well as contributed all of its non-clinical and clinical data generated to date. G-treeBNT will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones. In addition, RegeneRx has the right to approve key product licensing, mergers or acquisitions; receive a total of USD 1 million in two tranches, as well as royalties ranging from high single digits to low double digits, depending on medical indications approved and if the JV's ophthalmic product candidates are commercialised internally or through a third party; retain a significant equity position in the JV; and will not be required to provide any funding for the venture.

G-Treebnt Co., Ltd. Submits Phase IIB/III IND to Korean Health Authority for RGN 259

RegeneRx Biopharmaceuticals Inc. announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety (MFDS) for a Phase IIB/III clinical trial with RGN-259 (designated GBT-201 in Korea and the licensed Pan Asia territory) for the treatment of patients with dry eye syndrome. G-treeBNT received exclusive development and commercialization rights in March 2014 from RegeneRx for RGN-259 (GBT-201) for dry eye syndrome in 28 Asian and Pacific Rim countries including Korea, Japan and Australia. RegeneRx will receive royalties and milestone payments upon commercialization in the territory. RGN-259 (GBT-201) is a sterile, preservative-free topical eye drop for ophthalmic indications whose active ingredient is Thymosin beta 4 (TB4). Based on two U.S. Phase II clinical trials in moderate and severe dry eye syndrome, RGN-259 was found to show statistically significant improvements in several signs and symptoms of dry eye, as well as positive trends in other outcome measures. The results from these trials reflect RGN-259's mechanisms of action, appear to support the "protective" effects of RGN-259, and provide RegeneRx with FDA-approvable clinical endpoints to be targeted in future clinical trials.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
115450:KS 15,050.00 KRW +100.00

115450 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 115450.
View Industry Companies
 

Industry Analysis

115450

Industry Average

Valuation 115450 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.4x
Price/Book 12.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact G-TREEBNT CO LTD, please visit www.digitalaria.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.